Best of SABCS 2012 – Beirut, Lebanon – Scientific Program

UT Health Science Center San Antonio SABCS &
The American University of Beirut / Breast Center of Excellence – NK Basile Cancer Institute

BEST of SABCS – Beirut February 9, 2013

Speakers:

Yazid Belkacemi, MD, PhD (Paris, France)
David Cameron, MD (Edinburgh, UK)
Nagi El Saghir, MD, FACP (Beirut, Lebanon)
Ismail Jatoi, MD, PhD, FACS (U Texas, San Antonio, Texas, USA)

Conference Chair:
Nagi S. El Saghir, MD, FACP
Professor of Clinical Medicine / Hematology-Oncology
Director, Breast Center of Excellence, NK Basile Cancer Institute
American University of Beirut Medical Center, Beirut - Lebanon
Email: nagi.saghir@aub.edu.lb

8:00 am-9:00am: Registration & Welcome

9:00am – 10:00am
Surgery Oral Presentations:
Speaker: Ismail Jatoi, MD, PhD, FACS

S2-1. The role of sentinel lymph node surgery in patients presenting with node positive breast cancer (T0-T4, N1-2) who receive neoadjuvant chemotherapy – results from the ACOSOGZ1071 trial
**S2-2. Sentinel lymph node biopsy before or after neoadjuvant chemotherapy – final results from the prospective German, multinational SENTINA-trial**

**S2-3. Disparities in the utilization of axillary sentinel lymph node biopsy among black and white patients with node-negative breast cancer from 2002-2007**
Black DM, Jiang J, Kuerer HM, Buchholz TA, Smith BD. MD Anderson Cancer Center, Houston, TX.

**10:00-11:00 am:**
**Neo-Adjuvant Therapy Oral Presentations**
**Speaker: Nagi S. El Saghir, MD, AUBMC, Beirut, LB**

**S1-11. Meta-analysis Results from the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC)**

**S3-1. Neoadjuvant chemotherapy in the very young 35 years of age or younger**

**S3-6. Profiling of triple-negative breast cancers after neoadjuvant chemotherapy identifies targetable molecular alterations in the treatment-refractory residual disease**

**S4-5. Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trial**

**S4-6. An international Ki67 reproducibility study**
Nielsen TO, Polley M-YC, Leung SCY, Mastropasqua MG, Zabaglo LA, Bartlett JMS, Viale G, McShane LM, Hayes DF, Dowsett M, on Behalf of

**S6-4. Vitamin D, but not bone turnover markers, predict relapse in women with early breast cancer: An AZURE translational study**

**11:00 am - 11:15 am: Coffee Break**
**Radiation Therapy Oral Presentations**
**Speaker:** Yazid Belkacemi, MD (University of Paris, France)

**S4-1.** The UK START (Standardisation of Breast Radiotherapy) Trials: 10-Year follow-up results  

**S4-2. Targeted intraoperative radiotherapy for early breast cancer:** 
TARGIT – A trial – updated analysis of local recurrence and first analysis of survival  
Vaidya JS, Wenz F, Bulsara M, Joseph D, Tobias JS, Keshtgar M, Flyger

Plus a few abstracts selected from poster sessions on RT

**12:00 Noon – 1:00pm:**  
**Adjuvant therapy Oral Presentations I**  
**Speaker:** David Cameron, MD (Edinburgh, UK)

**S1-1.** Relative effectiveness of letrozole compared with tamoxifen for patients with lobular carcinoma in the BIG 1-98 trial  

**S1-2.** ATLAS – 10 v 5 years of adjuvant tamoxifen (TAM) in ER+ disease: Effects on outcome in the first and in the second decade after diagnosis  

**S1-3. Discussion**  
William E. Barlow, PHD, Fred Hutchinson Cancer Research Center, Seattle, WA

**S1-10.** Association between the 21–gene recurrence score (RS) and benefit from adjuvant paclitaxel (Pac) in node-positive (N+1), ER-positive breast cancer patients (pts): Results From NSABP B-28  

**S3-3.** The UK TACT2 Trial: comparison of standard vs accelerated epirubicin in patients requiring chemotherapy for early breast cancer (EBC) (CRUK/05/019)  
Cameron D, Barrett-Lee P, Canney P, Banerji J, Barlett J, Bloomfield
S3-4. Ten Year follow-up analysis of intense dose-dense adjuvant ETC (epirubicin (E), paclitaxel (T) and cyclophosphamide (C) confirms superior DFS and OS benefit in comparison to conventional dosed chemotherapy in high–risk breast cancer patients with ≥ 4 positive lymph nodes
Moebus V, Schneeweiss A, du Bois A, Lueck H-J, Eustermann H,

S4-4. Independent validation of Genomic Grade in the BIG 1-98 study

1:00 – 2:00 pm
Case Discussion (Lunch Hour)
Panel: All speakers and Chairs f sessions

2:00 pm – 3:00 pm
Adjuvant therapy Oral Presentations II
Speaker: David Cameron, MD (Edinburgh, UK)

S5-2. HERA TRIAL: 2 years versus 1 year of trastuzumab after adjuvant chemotherapy in women with HER2-Positive early breast cancer at 8 years of median follow up

S5-3. PHARE Trial results of subset analysis comparing 6 to 12 months of trastuzumab in adjuvant early breast cancer

S5-5. Trastuzumab plus adjuvant chemotherapy for HER2- positive breast cancer: Final planned joint analysis of overall survival (OS) from NSABP B-31 and NCCTG N9831

S5-7. Combined blockade of PI3K/AKT and EGFR/HER3 enhances anti-tumor activity in triple negative breast cancer

S6-5. Primary results of BEATRICE, a randomized phase III trial evaluating adjuvant bevacizumab-containing therapy in triple-negative breast cancer

S6-6. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes

3:00 pm – 4:00pm:
Treatment of Recurrent & Metastatic disease Oral Presentations:
Speaker: To Be announced

S1-6. Results of a randomized phase 2 study of PD 0332991, a cyclin-dependent kinase (cdk) 4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER+/HER2-advanced breast cancer (BC)
Finn RS, Crown JP, Lang I, Boer K, Bondarenko IM, Kulyk SO, Ettl J, Patel

S1-7. Phase III trial evaluating the addition of bevacizumab to endocrine therapy as first-line treatment for advanced breast cancer – First efficacy results from the LEA study

S3-2. Chemotherapy prolongs survival for isolated local or regional recurrence of breast cancer: the CALOR trial (Chemotherapy as adjuvant for locally Recurrent breast cancer; IBCSG 27-02, NSABP B-37, BIG 1-02)

S5-1. Biomarker analyses in CLEOPATRA: A phase III, placebo-controlled study of pertuzumab in HER2-positive, first-line metastatic breast cancer (MBC)
Baselga J, Cortes J, Im S-A, Clark E, Kiermaier A, Ross G, Swain SM.

S6-6. A Phase III, open-label, randomized, multicenter study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with anthracyclines and taxanes
Kaufman PA, Awada A, Twelves C, Yelle L, Perez EA, Wanders J, Olivo Ms, He Y, Dutcus CE, Cortes. Norris Cotton Cancer Center, Dartmouth

S6-7. Adaptive immune system and immune checkpoints are associated with response to pertuzumab (P) and trastuzumab (H) in the NeoSphere study

4:00 pm – 4:15pm: Coffee Break
4:15 pm - 6:00pm
Minisymposia summaries & Year-in-Review:

Surgery: Ismail Jatoi, MD, PhD
1- SLNB Before or after neoadjuvant chemotherapy (Eleftherios Mamounas, MD)
2- Evolving trends in implant breast reconstruction (Andrea L. Pusic, MD, MHS, FRCSC)
3- The role of MRI in management of primary breast cancer (Ismail Jatoi, MD, PhD, FACS)

Radiation Therapy: Yazid Belkacemi, MD, PhD
1- Breast Radiotherapy: Fractionation and Other Fashions (John Yarnold, MD)
2- Genetics and epidemiology of mammographic breast density (Celine M. Vachon, PhD)
3- Breast density: Mechanisms and clinical implications (Norman Boyd, MD, DSC)
4- Biological basis of breast density and cancer risk (Thea D. Tlsty, PhD)

Neo-adjuvant Therapy: Nagi El Saghir, MD
1- Neoadjuvant approach in HER2 over-expressing breast cancer: Therapeutic implications and biomarker discovery (Mothaffar Rimawi, MD)
2- Triple negative breast cancer: Subtypes, molecular targets, and therapeutic approaches (Jennifer A. Pietenpol, PhD; Samuel Aparicio, PhD; Thomas Westbrook, PhD)
3- Neoadjuvant Systemic Therapy: Promising Experimental Model, or Improved Standard of Care? (Gabriel N. Hortobagyi, MD)

Adjuvant Therapy: David Cameron, MD, PhD
1- Adjuvant therapy of HER2 positive breast cancer – the next installment (Karen Gelmon, MD)
2- Advances in HER2 + breast cancer (Nancy U. Lin, MD)

Metastatic Breast Cancer: To Be Announced
3- Basic research, Biology, Genomics, Clinical trials Designs for New Therapies (Susan G. Hilsenbeck, PhD, Angela DeMichele, MD, Clifford A. Hudis, MD, Sally Hunsberger, PhD, Susan G. Hilsenbeck, PhD)
1- The mTOR Pathway: Role in Metabolism and as a Therapeutic Target (Carlos L. Arteaga, MD; Lewis Cantley, PhD; Robert Schneider, PhD; Fabrice André, MD, PhD)

Saturday Morning Reviews
6:00 pm: Adjourn